Chronic kidney disease: Which medications can protect the kidneys, heart and blood vessels?

Photo of someone taking tablets

If the kidneys have not been working properly for more than three months or are so damaged that they are releasing increased amounts of proteins, then doctors consider the condition to be chronic kidney disease. Then medication can stop the disease from getting worse.

Various medications can be used to treat chronic kidney disease, depending on which stage it is in and what other medical problems you may have. The risk of complications also plays a role. The treatment should prevent more damage to the kidneys, keep them working for as long as possible, and prevent other complications. So often several medications are used. You can talk regularly with your doctors about whether the treatment needs to be adjusted to the disease or any side effects you notice.

Blood-pressure-lowering drugs

Whether drugs designed to lower blood pressure (also called antihypertensive drugs or simply antihypertensives) are an option for treating your chronic kidney disease will mostly depend on

  • how high your blood pressure is, and
  • how much protein is in your urine.

If you have chronic kidney disease, but normal levels of blood pressure and no protein (albumin) in your urine, you can get by without antihypertensive drugs. If you have high blood pressure or a lot of albumin in your urine, therapy with an ACE (angiotensin-converting enzyme) inhibitor or a sartan (angiotensin receptor blocker, or ARBs) is recommended if you also have diabetes, even if the albumin level is low.

Studies have shown that ACE inhibitors or sartans can lower high blood pressure levels in people with chronic kidney disease, decreasing the risk of complete kidney failure. Also, the therapy can lower the risk of cardiovascular disease, which is higher because of the kidney disease. These medications so not seem to help though if the kidney disease is already at a very advanced stage and dialysis is needed.

If in addition to chronic kidney disease you also have diabetes or your blood pressure is still too high even after taking ACE inhibitors or sartans, then doctors can give you an extra antihypertensive called a mineralocorticoid receptor antagonist (MRA or MCRA).

SGLT2 inhibitors

SGLT inhibitors, which were originally developed to lower blood sugar levels in people with diabetes, can slow the progression of chronic kidney disease and prevent complications. That is why they are also recommended, regardless of whether you have diabetes or not.

Cholesterol-lowering medications (statins)

Statins are medications that lower in the blood. They can help prevent heart and blood vessel problems. These medications are recommended because if you have chronic kidney disease, you also have a higher risk of those kinds of complications. They are probably most effective when the treatment is started early on. It is not known whether the medications can also prevent cardiovascular complications once you already need dialysis. But experts recommend that you continue taking the medications anyway.

It is also still not clear whether can slow down the progression of kidney disease as well.

Anti-clotting medication such as ASA

Anti-clotting medication – also described as blood thinners – such as acetylsalicylic acid (ASA, the drug found in Aspirin) reduce the blood's capacity to clot, so they can prevent a or stroke. They are used to treat chronic kidney disease if you also have a high risk of those kinds of complications, for example if you have already had a once.

Anti-clotting medication can also increase the risk of bleeding though, and ASA may make the kidneys work even worse, especially in advanced chronic kidney disease. So the pros and cons of these medications always need to be weighed carefully.

Medications for lowering uric acid

Uric acid salts can build up in the blood as a result of poor kidney function. If that ends up causing gout, medications like allopurinol are used to lower the levels of uric acid in your blood. The side effects of these drugs include rash and nausea.

It is not clear whether medication for lowering uric acid levels have additional advantages in the treatment of chronic kidney disease, such as slowing the progression of the disease.

Fleeman N, Pilkington G, Dundar Y et al. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technol Assess 2014; 18(40): 1-77, v-vi.

Georgianos PI, Tziatzios G, Roumeliotis S et al. Effect of angiotensin converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis. 2022; 38(1): 203-211.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2013 Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. 2013.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 2021.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD). 2022.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). 2024.

Liang X, Liu X, Li D et al. Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. Front Pharmacol 2022; 13: 798150.

National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NICE Clinical guidelines; No. 203). 2021.

Palmer SC, Di Micco L, Razavian M et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; (4): CD008834.

Palmer SC, Navaneethan SD, Craig JC et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; (5): CD007784.

Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev 2017; (10): CD009460.

Sanguankeo A, Upala S, Cheungpasitporn W et al. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLoS One 2015; 10(7): e0132970.

Sun L, Zou L, Chen M, Liu B. Meta-analysis of statin therapy in maintenance dialysis patients. Ren Fail 2015; 37(7): 1149-1156.

Taylor KS, McLellan J, Verbakel JY et al. Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. BMJ Open 2019; 9(9): e030596.

Tunnicliffe DJ, Palmer SC, Cashmore BA et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2023; 11(11): CD007784.

Xie X, Liu Y, Perkovic V et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016; 67(5): 728-741.

Zhang L, An K, Mou X et al. Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis. Front Pharmacol 2021; 12: 795082.

Zhang Z, Wu P, Zhang J et al. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016; 105: 74-83.

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas - either via our form or by gi-kontakt@iqwig.de. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Über diese Seite

Updated on September 11, 2024

Next planned update: 2027

Publisher:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.